Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aethlon Medical (AEMD) Cash from Financing Activities (2016 - 2025)

Aethlon Medical (AEMD) has disclosed Cash from Financing Activities for 15 consecutive years, with $2.4 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Cash from Financing Activities rose 5441.34% year-over-year to $2.4 million, compared with a TTM value of $7.7 million through Mar 2025, up 500.14%, and an annual FY2025 reading of $7.7 million, up 500.14% over the prior year.
  • Cash from Financing Activities was $2.4 million for Q1 2025 at Aethlon Medical, up from -$7073.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $17.4 million in Q2 2021 and bottomed at -$28134.0 in Q3 2021.
  • Average Cash from Financing Activities over 5 years is $2.1 million, with a median of -$1884.0 recorded in 2022.
  • The sharpest move saw Cash from Financing Activities skyrocketed 29600.95% in 2022, then crashed 103.99% in 2024.
  • Year by year, Cash from Financing Activities stood at -$13557.0 in 2021, then skyrocketed by 86.1% to -$1884.0 in 2022, then soared by 9501.75% to $177129.0 in 2023, then tumbled by 103.99% to -$7073.0 in 2024, then soared by 33453.03% to $2.4 million in 2025.
  • Business Quant data shows Cash from Financing Activities for AEMD at $2.4 million in Q1 2025, -$7073.0 in Q4 2024, and -$3832.0 in Q3 2024.